Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Small Cell Lung Carcinoma 1Rectal Diseases 1Pancreatic Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Colonic Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Peripheral Blood Stem Cell Transplantation 2Etoposide 2Cyclophosphamide 2tislelizumab 1sabarubicin 1guadecitabine 1fludarabine phosphate 1Radiotherapy 1Interleukin-12 Subunit p35 1Filgrastim 1Carboplatin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Testicular Germ Cell Tumor × guadecitabine × Clear all
NCT02429466 2020-09-23

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Indiana University

Phase 1 Completed
14 enrolled
Genitourinary

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡